Inflamyx ingredients target many metabolic pathways of the inflammatory response
1. Significant inhibition of the COX-2 (cyclooxygenase) enzyme, which produces prostaglandins PG-E2 (inflammatory) and thromboxanes TX-A2
(vasoconstrictive and increases platelet aggregation). The COX-2 inhibition is achieved by turmeric, ginger, quercetin and resveratrol. The PG-E2 is also
known to increase cell proliferation, which may be beneficial for normal tissue growth and wound healing but not for cancer promotion. That is why
inflammation is associated with the risk of cancer development in many studies and underscores the importance of keeping inflammation under control.
Additional inhibition of the expression of the COX-2 enzyme by antioxidant effects on NF-Kappa B, which is one of the regulators of the cytokine
(inflammatory) response. This is achieved by the antioxidant action of turmeric, quercetin, rutin, rosemary and resveratrol. This is a preferred mechanism of
inhibition because it acts upstream in the metabolic pathway by reducing oxidative stress, which can be one of the causes of inflammation. Thus, this is a
preventive action as opposed to blocking inflammation after it has started.
3. Inflamyx ingredients have a minimal inhibition of the COX-1 enzyme which
has a maintenance function for a number of tissues in the body, including intestinal cells. This is unlike aspirin or NSAIDs which are very irritating to the GI
4. Inflamyx has a mild anti-thrombotic (blood thinning) effect which could result in increased cardiovascular risk protection, similar to that of aspirin
yet without aspirin’s severe GI irritation. This blood thinning effect of Inflamyx is due to the following:
• mild COX-1 inhibition by ginger
• mild anti-
coagulating activity of turmeric and quercetin
• fibrinolytic effect of the proteolytic enzymes, especially the serratiopeptidase
5. Inflamyx may be
superior to selective COX-2 inhibitors like Vioxx and Celebrex due to the fact that, by design, they are lacking any COX-1 inhibiting activity, which affects
platelet aggregation. That is why drugs like Vioxx and Celebrex were shown in studies to increase the risk of thrombosis and overall CVD risk. This is
especially important for patients with low omega-3 fatty acid stores.
6. Inflamyx may be superior to selective COX-2 inhibiting drugs due to the fact that in
addition to inhibiting COX-2, some Inflamyx ingredients also inhibit the LOX (lipoxygenase) enzyme. This enzyme is normally producing leukotrienes (LT-4
series) which cause bronchoconstriction and vasoconstriction. The LOX inhibition is achieved through the action of boswellia, turmeric, ginger and quercetin.
7. Inflamyx may be superior to the typical anti-asthma drugs that are only leukotriene receptor blockers. This is because Inflamyx reduces the formation
of leukotrienes (LT) in the first place as opposed to just blocking certain LT receptors, as the drugs do.
8. One additional advantage that Inflamyx has
over selective anti-inflammatory drugs is that it combines many benefits in one, blocking various pathways at the same time. When any one drug is given, it
only blocks one arachidonic acid (AA) pathway. For example, Vioxx and Celebrex block only COX-2, which causes an overflow of AA into the other pathway,
the LOX-1. That is why COX-2 inhibiting drugs are known to have side effects such as increased incidence of asthma.
9. Some of Inflamyx’s ingredients
were shown to block phospholipase A2 (turmeric, ginger) or TNF-alpha (quercetin), which is similar to what corticosteroids do, but without their side effects.
• The flavonoid rutin reduces glycation (in addition to its anti-inflammatory and antioxidant properties).
• Serratiopeptidase improves the efficacy of
antibiotic treatment and relieves sinus congestion via mucolytic effects.
1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of
cyclooxygenase-2. N Engl J Med. 2001 Aug 9;345(6):433-42.
2. De Caterina R, Zampolli A. From asthma to atherosclerosis–5-lipoxygenase,
leukotrienes, and inflammation. N Engl J Med. 2004 Jan 1;350(1):4-7.
3. Ammon HP, Safayhi H. Mechanism of antiinflammatory actions of curcumine
and boswellic acids. J Ethnopharmacol. 1993 Mar; 38(2-3):113-9.
4. Kiuchi F, Iwakami S. Inhibition of prostaglandin and leukotriene biosynthesis by
gingerols and diarylheptanoids. Chem Pharm Bull (Tokyo). 1992 Feb; 40(2): 387-91.
5. Guardia T, Rotelli AE. Anti-inflammatory properties of plant
flavonoids. Effects of rutin, quercetin and hesperidinon adjuvant arthritis in rat. Farmaco. 2001 Sep;56(9):683-7.
6. Lo AH, Liang YC. Carnosol, an
antioxidant in rosemary, suppresses inducible nitric oxide synthase through down-regulating nuclear factor-kappaB in mouse macrophages. Carcinogenesis.
7. Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a
short review. Food Chem Toxicol 2002 Aug;40(8):1091-7.
8. Satoskar RR, Shah SJ. Evaluation of anti-inflammatory property of curcumin (diferuloyl
methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986 Dec; 24(12): 651-4.